Merck & Co. sought patent protection for a way to reduce cardiovascular problems in Cox-2 inhibitors, the class of drugs that includes Vioxx, as early as 1998, a year before the popular pain killer was introduced, newly disclosed documents show. Mark Lanier, the lawyer who last week won a $253.4 million verdict against Merck, said the application is further evidence that the company knew about the drug's dangers. But a Merck lawyer said the company was trying to enhance the class of drugs, not hide defects.
August 23, 2005 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Presented by BigVoodoo
This conference aims to help insurers and litigators better manage complex claims and litigation.
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
Legalweek New York explores Business and Regulatory Trends, Technology and Talent drivers impacting law firms.
The New Jersey State Commission of Investigation (SCI) is seeking an experienced and visionary leader to serve as its next Executive Directo...
We are a boutique firm specializing the area of real estate law and handling both litigation and transactional matters. We are seeking an as...
Rabb, Hamill, P.A, located in Woodbridge, NJ, seeks an experienced NJ licensed Personal Injury Trial attorney. The successful candidate wi...